US pharma major Bristol-Myers Squibb (NYSE: BMY) announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endpoints while demonstrating durable responses.
Liso-cel is a CD19-directed CAR-T cell therapy with a defined composition of purified CD8+ and CD4+ CAR-T cells, and it is being investigated in the TRANSCEND NHL 001 trial in relapsed/refractory large B-cell lymphomas.
The latest results were presented at the ongoing ASH event.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze